Expert Interview
Discussing Gossamer Bio’s Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) in treating PAH (Pulmonary Arterial Hypertension)
Ticker(s): GOSSA Pulmonologist or cardiologist with experience in treating Pulmonary Arterial Hypertension.
Please describe your practice as a clinician,how many patients with PAH do you see on a yearly basis? Could you walk us through the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
How much of an unmet need is there in PAH? How does Seralutinib compare to standard of care?
Added By: slingshot_insightsHow much use do you see for Seralutinib in the future? How likely are you to prescribe it to your patients?
The study reported a mean difference in PVR between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%. What are your high level thoughts regarding that data point?
In FC III patients, a 21% reduction in PVR (p = 0.0427) and 37m improvement in 6MWD (p = 0.0476) were observed for the seralutinib arm vs. placebo. In patients with a baseline REVEAL 2.0 Risk Score of 6 or greater, a 23% reduction in PVR (p = 0.0134) and 22m improvement in 6MWD (p = 0.2482) were observed for the seralutinib arm vs. placebo. How do these results compare to your patients’ responses to standard of care treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
